Compare Stocks: JANX, DNLI, LEGN, and RCUS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNLI Denali Therapeutics	$24.17 +4.4%	$23.30	$12.58 ▼ $27.30	$3.67B	1.01	1.72 million shs	993,574 shs
JANX Janux Therapeutics	$15.96 +4.2%	$14.96	$12.12 ▼ $35.34	$934.28M	2.5	839,372 shs	564,662 shs
LEGN Legend Biotech	$19.13 +0.6%	$27.57	$16.24 ▼ $39.16	$3.53B	0.37	2.67 million shs	2.57 million shs
RCUS Arcus Biosciences	$28.81 +4.3%	$27.18	$8.88 ▼ $31.74	$3.47B	0.8	1.02 million shs	845,208 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNLI Denali Therapeutics	+4.41%	+0.50%	-6.43%	+18.34%	+67.38%
JANX Janux Therapeutics	+4.18%	+6.40%	+2.70%	+9.17%	-33.25%
LEGN Legend Biotech	+0.63%	+0.47%	-36.04%	-33.94%	-50.25%
RCUS Arcus Biosciences	+4.01%	+6.25%	-5.29%	+10.40%	+212.65%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNLI Denali Therapeutics	$24.17 +4.4%	$23.30	$12.58 ▼ $27.30	$3.67B	1.01	1.72 million shs	993,574 shs
JANX Janux Therapeutics	$15.96 +4.2%	$14.96	$12.12 ▼ $35.34	$934.28M	2.5	839,372 shs	564,662 shs
LEGN Legend Biotech	$19.13 +0.6%	$27.57	$16.24 ▼ $39.16	$3.53B	0.37	2.67 million shs	2.57 million shs
RCUS Arcus Biosciences	$28.81 +4.3%	$27.18	$8.88 ▼ $31.74	$3.47B	0.8	1.02 million shs	845,208 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNLI Denali Therapeutics	+4.41%	+0.50%	-6.43%	+18.34%	+67.38%
JANX Janux Therapeutics	+4.18%	+6.40%	+2.70%	+9.17%	-33.25%
LEGN Legend Biotech	+0.63%	+0.47%	-36.04%	-33.94%	-50.25%
RCUS Arcus Biosciences	+4.01%	+6.25%	-5.29%	+10.40%	+212.65%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNLI Denali Therapeutics	2.75	Moderate Buy	$35.17	45.50% Upside
JANX Janux Therapeutics	2.50	Moderate Buy	$38.08	138.62% Upside
LEGN Legend Biotech	2.53	Moderate Buy	$55.29	189.00% Upside
RCUS Arcus Biosciences	2.58	Moderate Buy	$36.40	26.34% Upside

Current Analyst Ratings Breakdown

Latest JANX, DNLI, LEGN, and RCUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	LEGN Legend Biotech	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/28/2026	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
7/27/2026	LEGN Legend Biotech	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$49.00 ➝ $28.00
7/27/2026	LEGN Legend Biotech	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$58.00
7/27/2026	LEGN Legend Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$63.00 ➝ $59.00
7/24/2026	LEGN Legend Biotech	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$49.00 ➝ $28.00
7/23/2026	DNLI Denali Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$35.00 ➝ $36.00
7/20/2026	JANX Janux Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/20/2026	RCUS Arcus Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $45.00
7/17/2026	DNLI Denali Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNLI Denali Therapeutics	$330.53M	11.61	N/A	N/A	$6.91 per share	3.50
JANX Janux Therapeutics	$10M	97.32	N/A	N/A	$15.91 per share	1.00
LEGN Legend Biotech	$1.03B	3.45	N/A	N/A	$5.43 per share	3.52
RCUS Arcus Biosciences	$247M	14.67	N/A	N/A	$5.84 per share	4.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNLI Denali Therapeutics	-$512.54M	-$2.88	N/A	N/A	N/A	N/A	-52.20%	-43.86%	8/6/2026 (Estimated)
JANX Janux Therapeutics	-$113.62M	-$1.84	N/A	N/A	N/A	N/A	-12.93%	-12.23%	8/6/2026 (Estimated)
LEGN Legend Biotech	-$296.80M	-$0.68	N/A	12.26	N/A	-21.98%	-24.92%	-14.87%	8/11/2026 (Estimated)
RCUS Arcus Biosciences	-$353M	-$3.18	N/A	N/A	N/A	-156.36%	-68.97%	-35.27%	8/5/2026 (Estimated)

Latest JANX, DNLI, LEGN, and RCUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	LEGN Legend Biotech	$0.0563	N/A	N/A	N/A	$355.96 million	N/A
8/6/2026	Q2 2026	DNLI Denali Therapeutics	-$0.5131	N/A	N/A	N/A	$2.15 million	N/A
8/6/2026	Q2 2026	JANX Janux Therapeutics	-$0.26	N/A	N/A	N/A	$19.08 million	N/A
8/5/2026	Q2 2026	RCUS Arcus Biosciences	-$0.8912	N/A	N/A	N/A	$21.98 million	N/A
5/13/2026	Q1 2026	LEGN Legend Biotech	-$0.02	-$0.03	-$0.01	-$0.30	$306.51 million	$305.10 million
5/7/2026	Q1 2026	DNLI Denali Therapeutics	-$0.73	-$0.69	+$0.04	-$0.69	$2.57 million	N/A
5/7/2026	Q1 2026	JANX Janux Therapeutics	-$0.5202	-$0.39	+$0.1302	-$0.39	$4.36 million	$3.73 million
5/5/2026	Q1 2026	RCUS Arcus Biosciences	-$0.92	-$1.02	-$0.10	-$1.02	$29.49 million	$17.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNLI Denali Therapeutics	0.01	9.28	9.28
JANX Janux Therapeutics	N/A	17.01	17.01
LEGN Legend Biotech	N/A	2.13	2.05
RCUS Arcus Biosciences	0.19	4.04	4.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNLI Denali Therapeutics	92.92%
JANX Janux Therapeutics	75.39%
LEGN Legend Biotech	70.89%
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
DNLI Denali Therapeutics	9.70%
JANX Janux Therapeutics	7.90%
LEGN Legend Biotech	0.02%
RCUS Arcus Biosciences	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNLI Denali Therapeutics	430	158.71 million	143.32 million	Optionable
JANX Janux Therapeutics	30	60.98 million	56.17 million	Optionable
LEGN Legend Biotech	2,965	185.74 million	185.70 million	Optionable
RCUS Arcus Biosciences	500	125.77 million	116.21 million	Optionable

JANX, DNLI, LEGN, and RCUS Headlines

Recent News About These Companies

Dimensional Fund Advisors LP Has $30.80 Million Stake in Arcus Biosciences, Inc. $RCUS

4 hours ago | marketbeat.com

Earnings To Watch: Arcus Biosciences Inc (RCUS) Q2 2026 -- GF Value Sees 75% Downside

August 4 at 1:01 PM | finance.yahoo.com

Arcus Biosciences, Inc. $RCUS Shares Acquired by Renaissance Technologies LLC

August 3 at 4:48 AM | marketbeat.com

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

July 29, 2026 | globenewswire.com

Arcus Biosciences (RCUS) Projected to Post Quarterly Earnings on Wednesday

July 29, 2026 | marketbeat.com

Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

July 28, 2026 | americanbankingnews.com

Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of "Moderate Buy" by Analysts

July 28, 2026 | marketbeat.com

Arcus Biosciences Announces New Employment Inducement Grants

July 27, 2026 | businesswire.com

Arcus: 'Buy' On Casdatifan Late-Stage CcRCC Advancement And 1st-Line Expansions

July 24, 2026 | seekingalpha.com

Knott David M Jr Trims Stake in Arcus Biosciences, Inc. $RCUS

July 24, 2026 | marketbeat.com

Illinois Municipal Retirement Fund Invests $783,000 in Arcus Biosciences, Inc. $RCUS

July 24, 2026 | marketbeat.com

SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study

July 23, 2026 | zacks.com

Decheng Capital LLC Reduces Stock Holdings in Arcus Biosciences, Inc. $RCUS

July 23, 2026 | marketbeat.com

Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients

July 22, 2026 | businesswire.com

Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

July 22, 2026 | businesswire.com

What is HC Wainwright's Forecast for RCUS FY2029 Earnings?

July 22, 2026 | marketbeat.com

Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates

July 21, 2026 | businesswire.com

Arcus Biosciences (NYSE:RCUS) Stock Price Up 6.6% on Analyst Upgrade

July 20, 2026 | marketbeat.com

Arcus Biosciences (NYSE:RCUS) Price Target Raised to $45.00

July 20, 2026 | marketbeat.com

Arcus Biosciences (NYSE:RCUS) President Juan Jaen Sells 20,067 Shares

July 14, 2026 | insidertrades.com

An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run

July 13, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX, DNLI, LEGN, and RCUS Company Descriptions

Denali Therapeutics NASDAQ:DNLI

$24.17 +1.02 (+4.41%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$24.22 +0.05 (+0.21%)

As of 07:10 AM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Janux Therapeutics NASDAQ:JANX

$15.96 +0.64 (+4.18%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$16.00 +0.04 (+0.23%)

As of 07:54 AM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Legend Biotech NASDAQ:LEGN

$19.13 +0.12 (+0.63%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$19.20 +0.07 (+0.35%)

As of 07:52 AM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Arcus Biosciences NYSE:RCUS

$28.81 +1.19 (+4.31%)

Closing price 08/4/2026 03:59 PM Eastern

Extended Trading

$28.82 +0.00 (+0.01%)

As of 07:33 AM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JANX, DNLI, LEGN, and RCUS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JANX, DNLI, LEGN, and RCUS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JANX, DNLI, LEGN, and RCUS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX, DNLI, LEGN, and RCUS Company Descriptions

Denali Therapeutics NASDAQ:DNLI

Janux Therapeutics NASDAQ:JANX

Legend Biotech NASDAQ:LEGN

Arcus Biosciences NYSE:RCUS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JANX, DNLI, LEGN, and RCUS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JANX, DNLI, LEGN, and RCUS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JANX, DNLI, LEGN, and RCUS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX, DNLI, LEGN, and RCUS Company Descriptions

Denali Therapeutics NASDAQ:DNLI

Janux Therapeutics NASDAQ:JANX

Legend Biotech NASDAQ:LEGN

Arcus Biosciences NYSE:RCUS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools